- $2.05bn
- $1.53bn
- $6.94m
Brief: Immunome Completes Acquisition Of AL102, A Phase 3 Asset For Treatment Of Desmoid Tumors
Brief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-CME Group, Robinhood Markets, Citigroup
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome Announces Pricing Of Public Offering Of Common Stock
Brief: Immunome To Issue And Sell $200 Million Of Shares Of Its Common Stock
U.S. RESEARCH ROUNDUP-Crown Holdings, Waters Corp, West Pharmaceutical Service
U.S. RESEARCH ROUNDUP-Meta Platforms, Qualcomm, Visa
Brief: Immunome Exclusively Licenses Zentalis Ror1 Antibody-Drug Conjugate
Brief: Immunome And Corleen Roche Agreed To A Mutual Separation Effective January 2, 2024
Brief: Immunome To Acquire Antibody-Related Assets And Materials From Atreca
Brief: Immunome Files For Resale Of Up To 21.7 Mln Shares Of Common Stock - SEC Filing
Brief: Immunome Appoints Jean-Jacques Bienaimé to Board
Immunome Inc expected to post a loss of 16 cents a share - Earnings Preview
Immunome rises on merger agreement, $125 million private placement
Brief: Immunome And Morphimmune Announce Definitive Merger Agreement And Simultaneous Private Placement Investment Of $125 Million To Develop Targeted Cancer Therapies
Immunome Inc reports results for the quarter ended in March - Earnings Summary